WBB Securities President Dr. Steve Brozak examines five urgent questions emerging from the WHO’s emergency Hantavirus meeting, including transmission risks, global preparedness, and the broader implications for public health systems in a post-pandemic environment.
Read More about 5 Urgent Questions After The WHO Emergency Hantavirus Meeting – Published in ForbesIn a recent Forbes article, Dr. Steve Brozak examines HHS Secretary Robert F. Kennedy Jr.’s focus on the mental health crisis and the growing concern around psychiatric overprescribing.
Read More about Our Mental Health Crisis: RFK Jr. Faces Psychiatric Over-Prescribing – Published in ForbesNew insight from WBB Securities President Dr. Steve Brozak in Forbes.
In “The U.S. 2026 Healthcare Cliff: When the Business Model Is the Real Risk,” Steve explores how the potential expiration of enhanced ACA subsidies could expose longstanding structural weaknesses in the U.S. healthcare system, from reimbursement incentives to rising costs and access challenges.
The article highlights why this moment matters for healthcare companies, investors, policymakers, and patients alike.
In his latest Forbes article, WBB Securities President Dr. Steve Brozak examines the hidden dangers behind recent Medicaid funding cuts buried within a sweeping federal spending bill. Titled “Diagnosing Medicaid Cuts To Hospitals In The One Big Beautiful Bill”
Read More about Diagnosing Medicaid Cuts To Hospitals In The One, Big, Beautiful Bill – Published in ForbesDr. Steve Brozak, President of WBB Securities, has authored a new opinion piece in Forbes
Read More about President Donald Trump – Will He Become the Drug Price Equalizer?
WBB Securities is pleased to share a featured interview with our Managing Director, Dr. Steve Brozak, published in The Wall Street Transcript on April 29, 2025.
Read More about Onshoring Drug Manufacturing Is Critical But Not Easy